Mercedeh Ghadessi

Mercedeh Ghadessi

Auto-generated profile, based on publicly available information

Mercedeh Ghadessi

Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
RLRong Liu
Rong Liu
ZLZheyu Liu
Zheyu Liu
MGMercedeh Ghadessi
Mercedeh Ghadessi
RVRichardus Vonk
Richardus Vonk

1 April 2014 in European Urology Supplements
Verified
Journal Article
Closed access
AMA.P. Mitra
A.P. Mitra
LLL.L. Lam
L.L. Lam
MGM. Ghadessi
M. Ghadessi
NEN. Erho
N. Erho
IVI.A. Vergara
I.A. Vergara
PBP.C. Black
P.C. Black

1 November 2025 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
NSNeil Shore
Neil Shore
DGDaniel James George
Daniel James George
NKNasreen Khan
Nasreen Khan
NCNiculae Constantinovici
Niculae Constantinovici
GCGuifang Chen
Guifang Chen
AMAlicia K. Morgans
Alicia K. Morgans

20 October 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NENicholas Erho
Nicholas Erho
IVIsmael A. Vergara
Ismael A. Vergara
CBChristine Buerki
Christine Buerki
MGMercedeh Ghadessi
Mercedeh Ghadessi
ACAnamaria Crisan
Anamaria Crisan
EDElai Davicioni
Elai Davicioni
40 Background: Gleason score (GS) is the most widely used grading system of cell differentiation in prostate cancer and one of the best pathological predictors of disease progression. Patients with high GS (> 7) are the most likely to experience metastasis, whereas patients with low GS (< 7) are expected to have favorable long-term outcomes. In addition to the subjective nature of GS assessment, patients with GS 7 represent a heterogeneous group in terms of patient outcomes. In this study a biomarker signature is developed and validated which could improve the prediction of high risk disease among GS 7 radical prostatectomy (RP) patients. Methods: Patient specimens from the Mayo Clinic RP Registry (n = 764) were used for feature selection and training of a 392-feature K-nearest neighbor (KNN, k = 11) classifier. These 392 genomic features were identified by assessing differential expression between patients with GS < 7 and those with GS > 7, using a Bonferroni adjusted T-Test with a p-value threshold of 0.05. The classifier was subsequently validated in two independent patient cohorts (Memorial Sloan Kettering [MSKCC] and German Cancer Research Center [DKFZ]) and compared to a state of the art biomarker signature (Penney et al. 2011). Results: In the MSKCC dataset (GSE21034) our model segregated GS < 7 from GS > 7 patients (n = 56) with an area under the receiver operating characteristic curve (AUC) of 0.97, comparable to the AUC of 0.94 obtained by Penney et al. in their independent validation set (n = 45). Strong performance was observed by our model when discriminating between primary Gleason grade (pGG) 3 and pGG 4 & 5 patients in the MSKCC (n = 130) and DKFZ prostate cancer (GSE29079, n = 47) datasets, achieving AUCs of 0.75 and 0.87, respectively. In the challenging GS 7 subset, our model segregated GS 3 + 4 and 4 + 3 patients in the DKFZ dataset (n = 64) with an AUC of 0.81 outperforming the Penney et al. signature (AUC = 0.60). Conclusions: A biomarker signature was developed which discriminates between low and high GS patients, outperforming a previously reported signature. Further validation of this biomarker signature in additional post RP patients, as well as, pretreatment biopsy specimens is warranted.